OSR Health Evaluates Options After Nasdaq Delisting Decision
OSR Health is reviewing strategic and corporate alternatives after the Nasdaq Hearings Panel determined to delist its securities for non-compliance with the $1.00 minimum bid price requirement.
OSR Health, Inc. (OTC PINK:OSRH) is assessing possible routes back to a national securities exchange after the Nasdaq Hearings Panel determined to delist the company’s securities. The healthcare holding company said it expects to provide a further update on its plans on or before November 6, 2026.
The panel made its determination on October 23, 2026, citing non-compliance with Nasdaq’s $1.00 minimum bid price requirement. Trading in OSR Health’s shares on Nasdaq was suspended on August 26, 2026, and the common stock has since been quoted on the over-the-counter market under the symbol “OSRH.”
The company said the Nasdaq decision does not change its status as an SEC-reporting company. During the compliance process, OSR Health said it did not pursue a reverse stock split and instead sought to address the listing issue through business initiatives.
OSR Health said maintaining a listing on a national securities exchange remains a priority. It is reviewing several options for meeting applicable listing standards, including strategic and corporate alternatives. The company has not stated which route it will pursue or whether any option will enable it to regain a national exchange listing.
OSR Health identified risks related to the outcome of any option it pursues and its ability to satisfy listing standards. The company said further risks are described in its SEC filings.
The company said its $15 million equity put option against BCM Europe AG under the Global Exclusive License Agreement for VXM01 remains in place. Following an amendment dated October 15, 2026, the arrangement may also be settled through convertible notes for an equal amount of the principal, $15 million, at fixed conversion prices of approximately $2.00 to $5.00 per share.
OSR Health said the availability of funding is subject to BCM Europe AG or a designated purchaser being able to meet its obligations. The company’s forward-looking statements also carry risks and uncertainties that could cause actual results to differ materially.
OSR Health said it intends to seek continuation of its Shareholder Loyalty CVR Program for enrolled holders. This may involve amending the CVR Agreement so that price thresholds are assessed using the principal market where the common stock is then listed or quoted.
The company said enrolled holders will receive updates as the process develops. It also identified the ability to amend the CVR Agreement on acceptable terms as a risk connected with the plan.
Development is continuing across OSR Health’s portfolio. Vaximm is preparing a publication of new data analysis from the completed Phase 2a trial in glioblastoma involving VXM01, which the company describes as an oral T-cell immunotherapy.
Darnatein’s regenerative protein programmes remain the subject of licensing discussions with a potential licensee. OSR Health also said numerous parties from around the globe have expressed interest in potential partnerships involving Woori IO’s noninvasive glucose monitoring technology.
The Nasdaq Hearings Panel determined on October 23, 2026, to delist OSR Health’s securities over non-compliance with the $1.00 minimum bid price requirement.
OSR Health’s common stock is quoted over the counter under “OSRH,” while the company remains an SEC-reporting company.
The company is evaluating strategic and corporate alternatives and plans to provide a further update on or before November 6, 2026.
The $15 million VXM01 funding mechanism remains in place, with convertible-note settlement available under the October 15, 2026 amendment.
OSR Health intends to seek continuation of its Shareholder Loyalty CVR Program and reported ongoing development and partnership discussions across its pipeline.
OSR Health announced a shareholder update following the Nasdaq Hearings Panel's decision to delist the Company's securities from The Nasdaq Stock Market. The Company said it is evaluating options to regain compliance, expects to provide a further update on or before November 6, 2026, and remains focused on its funding mechanism, shareholder programme and pipeline development.
The Nasdaq Hearings Panel decided to delist OSR Health's securities for non-compliance with Nasdaq's $1.00 minimum bid price requirement. The decision was made on October 23, 2026.
OSR Health's common stock is currently quoted on the over-the-counter market under the symbol "OSRH". Trading on Nasdaq was suspended on August 26, 2026, and the Company said the Nasdaq decision does not affect its status as an SEC-reporting company.
OSR Health is evaluating a range of options to regain compliance with applicable listing standards, including strategic and corporate alternatives. The Company said returning to a national securities exchange remains a priority, but the outcome of any option it may pursue is subject to risks and uncertainties.
OSR Health intends to provide a further update on its plan to regain a national securities exchange listing on or before November 6, 2026. The Company has not stated the outcome of its evaluation of available options.
OSR Health said it chose not to pursue a reverse stock split during the compliance process. The Company said it instead sought to regain compliance through organic value-creating initiatives.
OSR Health said its $15 million equity put option against BCM Europe AG under the Global Exclusive License Agreement for VXM01 remains in place. As amended on October 15, 2026, the mechanism may also be settled through convertible notes for an equal amount of the principal, $15 million, at fixed conversion prices of approximately $2.00 to $5.00 per share.
OSR Health said the availability of funding under its agreements depends on BCM Europe AG or a designated purchaser being able to fund its obligations. The Company also said its forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
OSR Health intends to seek to continue its Shareholder Loyalty CVR Program for enrolled holders. The Company said this may include amending the CVR Agreement so that price thresholds are measured on the principal market on which its common stock is then listed or quoted, with enrolled holders to be updated as the process progresses.
OSR Health is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, it engages in immuno-oncology, regenerative biologics and medical device technologies, and its CEO said the Company operates with a Hub-and-Spoke business structure.
Development continues for VXM01, which OSR Health describes as Vaximm's oral T-cell immunotherapy. Vaximm is currently preparing a publication of its new data analysis on the completed Phase 2a trial in glioblastoma.
OSR Health said Darnatein's regenerative protein programmes continue to be the subject of licensing discussions with a potential licensee. It also said numerous parties from around the globe have expressed interest in potential partnerships involving Woori IO's noninvasive glucose monitoring technology.
OSR Health said risks include the outcome of any option it may pursue, its ability to satisfy listing standards and its ability to amend the CVR Agreement on acceptable terms. The Company said these forward-looking statements are also subject to other risks described in its SEC filings.